Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1995-4-6
|
pubmed:abstractText |
Twenty two healthy males participated in a randomised, placebo-controlled, double blind, cross-over study to investigate the influence of simvastatin on the pharmacokinetics of ramipril and its active metabolite (ramiprilat), and on the ACE-inhibiting effect of ramiprilat. During two study periods, each of 7 days, subjects received daily either simvastatin 20 mg at 19.00 h or placebo; ramipril (5 mg) was given on Day 5 of each of the periods. Plasma concentrations of ramipril and ramiprilat and ACE-activity were measured in sequential blood specimens, and ramipril and ramiprilat concentrations were measured in urine. Blood and urine collections for pharmacokinetic and pharmacodynamic assessment were made up to 72 h after the dose of ramipril. The mean AUC of ramipril for ramipril+placebo (R+P) and ramipril+simvastatin (R+S) was 22.2 and 21.3 ng.h.ml-1, respectively; for ramiprilat the corresponding figures were 61.3 and 57.6 ng.h.ml-1. The urinary excretion of ramipril+metabolites for (R+P) and (R+S) was 25.2 and 24.1% of dose. The maximum percentage inhibition of ACE-activity for (R+P) was 94.6%, and for (R+S) it was 94.1%. It is concluded that concomitant administration of simvastatin and ramipril has no clinically relevant effect on the pharmacokinetics or ACE-inhibition of the latter drug and its metabolites.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin-Converting Enzyme...,
http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin,
http://linkedlifedata.com/resource/pubmed/chemical/Ramipril,
http://linkedlifedata.com/resource/pubmed/chemical/Simvastatin
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0031-6970
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
47
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
373-5
|
pubmed:dateRevised |
2010-11-18
|
pubmed:meshHeading |
pubmed-meshheading:7875191-Adult,
pubmed-meshheading:7875191-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:7875191-Biological Availability,
pubmed-meshheading:7875191-Child,
pubmed-meshheading:7875191-Cross-Over Studies,
pubmed-meshheading:7875191-Double-Blind Method,
pubmed-meshheading:7875191-Drug Interactions,
pubmed-meshheading:7875191-Humans,
pubmed-meshheading:7875191-Hypolipidemic Agents,
pubmed-meshheading:7875191-Lovastatin,
pubmed-meshheading:7875191-Male,
pubmed-meshheading:7875191-Ramipril,
pubmed-meshheading:7875191-Simvastatin
|
pubmed:year |
1994
|
pubmed:articleTitle |
Lack of interaction between ramipril and simvastatin.
|
pubmed:affiliation |
Hoechst Clinic, Department of Pharmacology (G6), University of the Orange Free State, Bloemfontein, South Africa.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|